Cover Image

Influence of Sulfonylurea and Insulin on Immunological Profile of Type 2 diabetic Egyptian Patients

Zeinab Saied, Azza El Amir, Hisham EL Hefnawy, Ahmed Afifi

Abstract


Type 2 diabetes mellitus (T2DM) is a chronic, inflammatory disease caused by long-term imbalance in immune system, metabolic syndrome, or nutrient excess associated with obesity .Sulfonylurea and exogenous insulin have been used in the treatment of T2DM, and they have hypoglycemic and anti-inflammatory effects .The aim of this study to demonstrate the effect of sulfonylurea and exogenous insulin on some immunological parameters in Egyptian patients with T2DM and determine whether diabetes or the type of treatment would influence the levels of these parameters.

Materials &Methods: This study was performed on 150 outpatients with type 2 diabetes matched with age and gender with 40 healthy subjects was selected from the outpatient’s clinics of National Institute for Diabetes and Endocrinology. All studied patients and control were subjected to estimate Fasting blood glucose (FBG), Glycosylated heamoglobulin (HBA1c), White blood cells (WBCs), Interleukin-6(IL-6), Immunoglobulin G (IgG) and Immunoglobulin A (IgA). Results: The levels of FBG, HBA1c, WBCs, IL-6, IgG and IgA showed highly significant increase in the diabetic patient groups compared to controls. (P˂0.001).Treatment of T2DM patients with sulfonylurea and insulin caused highly significant decrease in the levels of FBG, HBA1c as compared to corresponding non -treated group (P˂0.001). Also, the level of IL-6 revealed a highly significant decrease in insulin treated patients  as compared to corresponding non -treated group(p<0.001).While, non-significant change (p>0.05) in the levels of WBCs, IgG and IgA was observed in treated patient groups with sulfonylureas and insulin as compared to corresponding non -treated group.

Conclusion: Both sulfonylurea and insulin are immune- safe therapeutic agent in T2DM at dose achieve good glycemic control.


 

 


Keywords


Type 2 diabetes; Sulfonylurea; Insulin; Immunoglobulin; IL-6

References


Balogun FO, Tshabalala NT, and Ashafa AO. Antidiabetic Medicinal Plants Used by the Basotho Tribe of Eastern Free State. J Diabetes Res. 2016, volume 2016:4602820

Guzm´an-Flores JM, and ´opez-Briones SL. Cells of the innate and adaptive immunity in type 2 diabetes mellitus and obesity. Gaceta Medica de Mexico. 2012, 148(4): 381-389

Guarner V, and Rubio-Ruiz M E. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2014, 40:99-106

Nikolajczyk BS, et al. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011, 12:239-250

Elmessallamy FA, Nawara A, Sallam MM, and Elsaid HH. Serum immunoglobulin G (IgG) as a predictive marker of early renal affection in type 2 diabetic patients. Int J Adv Res. 2016, 4(12):542-549

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011, 11:98-107

Esser N, Legrand-Poels S, Piette J, Scheen AJ, and Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014, 105:141-150

Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, et al. Neutrophil: lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study. Eur J Endocrinol. 2015, 173:217-225

Guo X,Meng G, Liu F, Zhang Q, Liu L, Wu H, Du H, et al. Serum levels of immunoglobulins in an adult population and their relationship with type 2 diabetes. Diabetes Res Clin Pract. 2016, (3): 76-82

Nakamura I, Oyama J, Komoda H. et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: apreliminary report. Cardio Diabetology. 2014, 2014:13-15

American Diabetes Association. Classification and Diagnosis of diabetes mellitus. Diabetes Care. 2017, 40(1): S11-S24

Sun Q, Li J, and Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes. 2014, 5(2): 89-96

Dezayee ZM, and Alnakshabandi AA. Assessment of Some Immunological Parameters In Respect to Glycemic Control in Type I &Type II Diabetes:Comparative Study. Res J of med sci. 2011, 5(3):119-121

Moazezi Z, Hosseinian A, Moazam EA, Eslami MB, Mosavi E, et al. Evaluation of Immunological Parameters in Diabetic Patients: Are These Patients Immunodeficient? Iran J Allergy Asthma Immunol. 2014, 13(2):110-119

Antoniades C, Tousoulis D, Marinou K, Papageorgiou N, Bosinakou E, Tsioufis C, et al. Effects of Insulin Dependence on Inflammatory Process, Thrombotic Mechanisms and Endothelial Function, in Patients With Type 2 Diabetes Mellitus and Coronary Atherosclerosis. Clin Cardio. 2007, 30: 295-300

Mavridis G, Souliou E, Diza E, Symeonidis G, Pastore F, et al. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nut, Meta & Cardio Diseases. 2008, 18: 471-476

Jaber HH. Study of comparative between insulin, daonil drugs and effect on immune resistance in diabetes mellitus patient. Journal of Kerbala University. 2013, 11 (2):92-97

Shiwaku K, Anuurad E, Enkhmaa B, et al. Body-mass index forAsian populations for policy and intervention strategies. Lancet. 2004, 363: 157-163

ChaudhuryA, Duvoor C, Kraleti S, ChadaA, Ravilla R, Marco A, et al. Clinical review of antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontires in Endocrionology. 2017, 8:1-12

Eriksson A, Attvall S, Bonnier M, Eriksson JW, et al. Short-term effects of metformin in type 2 diabetes. Diab Obes Metab. 2007, 9:483-489

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012, 55: 1577-1596

Manssor AJ, and Rajab H. The effects of anti-diabetic agents on white blood cells. Journal of Pure Science. 2011, 16 (4): 1813 - 1662

Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999, 353:1649-1652

Klotsas EG, Ye Z, Cooper AJ, et al. Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies. PLoS ONE. 2010, (5):10

Dinauer MC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program. 2005, 2005:89-95

Van Wijk JP, Cabezas MC, Coll B, Joven J,Rabelink TJ, et al. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis. 2006, 186: 152-159

Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, et al. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. Horm Metab Res. 2009, 41: 132-136

Pradhan AD,Manson, JE, Rifai N, Buring JE, and Ridker PM. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 2011, 286:327-334

Ronti T, Lupattelli G, and Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol. 2006, 64:355-365

Kunimoto DY, Nordan RP, and Strober W. IL-6 is a potent cofactor of IL-1 in IgMsynthesis and of IL-5 in IgA synthesis. J Immunol. 1989,143:2230-2235

Browning LM, Krebs JD, and Jebb SA. Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. Metabolism. 2004, 53:899-903

LaishramV, Lamabam V, Laikangbam S, Dubey A, et al. Interleukin-6 in obese type II diabetes with hypertension. International Journal of Research in Medical Sciences. Res Med Sci. 2016,4(3):896-901

Nazari A, Sardoo AM, Fard ET, Hassanshahi G, Goujani R, et al. Is IL-6 Increased in Type 2 Diabetes Mellitus Patients Independent of Nephropathic Complication? J Endocrinol Diabetes Obes. 2017, 5(2): 1102

Al-Shukaili A, AL-Ghafri S, Al-Marhoobi S, Al-Abri S, et al. Analysis of Inflammatory Mediators in Type 2 Diabetes Patients. Inter J of Endocrinology. 2013, 2013:1-7

Vanden BG. Intensive insulin therapy in critically ill patients. New Eng J Med. 2001, 345: 1359-1367

Jeschke MG, Einspanier R, and Klein D. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med. 2002, 8: 443-450

Gonzalez A, Alende R, Gude F, Campos J, Rey J, Meilide LM, et al. Serum levels of Immunoglobulin (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin & Exp Immunology. 2008, 151 (1): 42-50

Alvarez F, Berg PA, and Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999, 31:929-938

Mohammed N, Tang L, Jahangiri A, et al. Elevated IgG levels against specific bacterial antigens in obese patients with diabetes and in mice with diet induced obesity and glucose intolerance. Metabolism. 2012, 61:1211-1214


Full Text: PDF

Refbacks

  • There are currently no refbacks.


AJDOM Copyright © 2012-2018. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States